Researchers from the University of Virginia have pinpointed the role of the Alzheimer’s risk gene CASS4 in the brain’s own immune cells, showing that deleting the gene in mice impairs microglial control of toxic amyloid plaques. The findings, published in the Journal of Experimental Medicine, indicate that CASS4 helps microglia anchor and move their internal machinery to surround and compress harmful deposits.
The study places CASS4, a member of a family of scaffold proteins, at the centre of microglial responses to amyloid pathology. While CASS4 has long been linked to cancer cell movement and scaffolding, its function in the brain has remained largely unknown. Microglia—the brain’s resident immune cells—are now shown to rely on CASS4 to form the focal adhesions that enable them to grip tissue, extend processes, and confront damaged areas.
Microglia’s grip on plaques under the spotlight
Alzheimer’s disease is characterised by amyloid-beta plaques and tangled tau fibres. Human brain mapping and single-cell analyses have highlighted microglia as key players in the disease, with genetic variations near microglial genes implicated in late-onset Alzheimer’s risk. CASS4 was first associated with risk in a 2013 genetic study, and this new work investigates what the gene does within brain tissue itself.
The researchers used gene editing to create mice lacking CASS4 throughout the body and crossed them with a model carrying five human mutations that drive rapid amyloid buildup. To ensure consistency in plaque development, all cohorts consisted of female mice, and each inherited the Alzheimer’s mutations from its father to control for parental effects on plaque burden.
At five months, their brains were examined with a plaque-detecting dye. The CASS4-deficient mice exhibited more numerous and larger plaques in the hippocampus and adjacent cortex compared with Alzheimer’s-model littermates that retained CASS4. The researchers also observed worse nerve-fibre damage near those deposits, including greater accumulation of the neuronal damage marker amyloid precursor protein and higher levels of ATG9, a cellular recycling protein that collects in unhealthy axons.
RNA sequencing of thousands of brain cells showed microglia were the main cells expressing CASS4, but gene expression shifts extended beyond microglia. In excitatory neurons, nearly 3,000 genes changed, with increased activity in pathways linked to spatial working memory and motor learning. In inhibitory neurons, more than 200 genes altered, including reduced expression of those maintaining neural circuitry.
The team also tested cognition using the Morris water maze. After four days of training, there was no clear difference in learning or memory between groups. When the platform was moved to test cognitive flexibility, the CASS4-deficient Alzheimer’s mice swam farther from the new location and persisted in the old one, unlike their CASS4-containing littermates.
Other behavioural tests found no significant differences in swim speed or anxiety-like behaviours, and a non-Alzheimer’s control group showed no deficits with CASS4 deletion, suggesting the cognitive inflexibility observed arose specifically in the context of amyloid pathology.
To understand microglial behaviour at the plaque border, the researchers used flow cytometry and single-nucleus sequencing. They found no significant differences in microglial numbers, division, activation markers, or the proportion engulfing amyloid-beta over short time frames. Instead, microglia lacking CASS4 formed fewer branches immediately adjacent to plaques, and the plaques themselves were less dense and less spherical, with more diffuse amyloid surrounding core deposits.
To isolate microglia’s role, the team created a conditional line in which CASS4 could be deleted later in life specifically in microglia and related immune cells. After inducing deletion post-weaning and allowing new blood-borne immune cells to replace older ones, long-lived brain microglia remained CASS4-deficient. These mice showed the same pattern of larger, poorly compacted plaques and increased nerve-fibre damage, despite unchanged microglial numbers.
Live imaging added another layer: in normal mice, microglia rapidly extended branches to a laser-induced injury in the cortex, but those lacking CASS4 showed a blunted response. The authors describe this as a striking demonstration that CASS4 underpins a key microglial reaction to brain injury.
Implications, caveats, and future directions
Lead author Adeline E. Walsh and senior author John R. Lukens emphasised that, despite CASS4’s clear role in microglial function, the work is early-stage and in mice. The study notes several caveats, including the lack of tau tangles in the model and the possibility that findings may not translate directly to humans. Deleting CASS4 across the whole body represents a more drastic change than the subtle human genetic variations linked to risk, and the experiments used only female mice to standardise plaque timing. Bone marrow-derived macrophages served as a stand-in for microglia in some experiments, though the live-brain imaging supported the microglial results.
Lukens described the broader significance: “Surprisingly, the microglia that were lacking CASS4 barely responded to the laser injury at all, suggesting that CASS4 plays a key role in this very important microglial function.” He also pointed to the potential for therapies: “This work suggests that therapeutics that promote CASS4 function in microglia could provide a novel strategy to limit Alzheimer’s disease progression.” He added that downregulation of CASS4 could serve as a biomarker for early disease stages and that supporting CASS4 pathways might help preserve microglial barriers against toxic amyloid-beta deposits.
The authors advocate pursuing first-in-class CASS4-targeting drugs to treat neurological disorders, including possible relevance to other conditions such as Parkinson’s disease, ALS and multiple sclerosis, in collaboration with the UVa Manning Institute. They emphasise that any therapeutic approach would represent a novel mechanism, aimed at strengthening the brain’s immune surveillance rather than simply removing plaques.
The study—titled Alzheimer’s genetic risk factor CASS4 controls microglial focal adhesion biology and amyloidosis—was led by Adeline E. Walsh with colleagues including Benjamin A. Davis, Joshua D. Samuels, and John R. Lukens of the University of Virginia.
